193 related articles for article (PubMed ID: 38448555)
21. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
22. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2
Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK
Front Immunol; 2022; 13():993444. PubMed ID: 36685592
[TBL] [Abstract][Full Text] [Related]
23. Discovery and expression of 3 siglecs-like in Oreochromis niloticus neutrophil, and their interaction with group B streptococcal sialylated capsular polysaccharides.
Dong J; Wei Y; Ye X; Sun C; Tian Y; Lu M; Du J; Chen Z
Mol Immunol; 2016 May; 73():158-69. PubMed ID: 26847490
[TBL] [Abstract][Full Text] [Related]
24. Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity.
Huang J; Li M; Mei B; Li J; Zhu Y; Guo Q; Huang J; Zhang G
J Transl Med; 2022 Oct; 20(1):496. PubMed ID: 36316782
[TBL] [Abstract][Full Text] [Related]
25. Sialoglycans on lymphatic endothelial cells augment interactions with Siglec-1 (CD169) of lymph node macrophages.
D'Addio M; Frey J; Tacconi C; Commerford CD; Halin C; Detmar M; Cummings RD; Otto VI
FASEB J; 2021 Nov; 35(11):e22017. PubMed ID: 34699642
[TBL] [Abstract][Full Text] [Related]
26. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
[TBL] [Abstract][Full Text] [Related]
27. Targeted glycan degradation potentiates the anticancer immune response in vivo.
Gray MA; Stanczak MA; Mantuano NR; Xiao H; Pijnenborg JFA; Malaker SA; Miller CL; Weidenbacher PA; Tanzo JT; Ahn G; Woods EC; Läubli H; Bertozzi CR
Nat Chem Biol; 2020 Dec; 16(12):1376-1384. PubMed ID: 32807964
[TBL] [Abstract][Full Text] [Related]
28. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
29. The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption.
Andes FT; Adam S; Hahn M; Aust O; Frey S; Grueneboom A; Nitschke L; Schett G; Steffen U
Bone; 2021 Feb; 143():115665. PubMed ID: 33007530
[TBL] [Abstract][Full Text] [Related]
30. Interaction of Group B Streptococcus sialylated capsular polysaccharides with host Siglec-like molecules dampens the inflammatory response in tilapia.
Dong J; Wei Y; Sun C; Tian Y; Hu J; Shi H; Zhang D; Lu M; Ye X
Mol Immunol; 2018 Nov; 103():182-190. PubMed ID: 30291999
[TBL] [Abstract][Full Text] [Related]
31. Exploring the Impact of Ketodeoxynonulosonic Acid in Host-Pathogen Interactions Using Uptake and Surface Display by Nontypeable Haemophilus influenzae.
Saha S; Coady A; Sasmal A; Kawanishi K; Choudhury B; Yu H; Sorensen RU; Inostroza J; Schoenhofen IC; Chen X; Münster-Kühnel A; Sato C; Kitajima K; Ram S; Nizet V; Varki A
mBio; 2021 Jan; 12(1):. PubMed ID: 33468699
[TBL] [Abstract][Full Text] [Related]
32. SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity.
Bouti P; Blans C; Klein BJAM; Shome D; Nadafi R; Van Houdt M; Schornagel K; Verkuijlen PJJH; Roos V; Reijmers RM; Van Bruggen R; Kuijpers TW; Matlung HL
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138970
[TBL] [Abstract][Full Text] [Related]
33. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
34. Mouse Siglec-1 Mediates trans-Infection of Surface-bound Murine Leukemia Virus in a Sialic Acid N-Acyl Side Chain-dependent Manner.
Erikson E; Wratil PR; Frank M; Ambiel I; Pahnke K; Pino M; Azadi P; Izquierdo-Useros N; Martinez-Picado J; Meier C; Schnaar RL; Crocker PR; Reutter W; Keppler OT
J Biol Chem; 2015 Nov; 290(45):27345-27359. PubMed ID: 26370074
[TBL] [Abstract][Full Text] [Related]
35. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.
Stanczak MA; Rodrigues Mantuano N; Kirchhammer N; Sanin DE; Jacob F; Coelho R; Everest-Dass AV; Wang J; Trefny MP; Monaco G; Bärenwaldt A; Gray MA; Petrone A; Kashyap AS; Glatz K; Kasenda B; Normington K; Broderick J; Peng L; Pearce OMT; Pearce EL; Bertozzi CR; Zippelius A; Läubli H
Sci Transl Med; 2022 Nov; 14(669):eabj1270. PubMed ID: 36322632
[TBL] [Abstract][Full Text] [Related]
36. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells.
Meril S; Harush O; Reboh Y; Matikhina T; Barliya T; Cohen CJ
Mol Carcinog; 2020 Jul; 59(7):713-723. PubMed ID: 32391973
[TBL] [Abstract][Full Text] [Related]
37. Sialic Acid-Siglec-E Interactions During
Mukherjee K; Khatua B; Mandal C
Front Immunol; 2020; 11():332. PubMed ID: 32184783
[No Abstract] [Full Text] [Related]
38. Sialic Acid-Siglec-E Interactions Regulate the Response of Neonatal Macrophages to Group B Streptococcus.
Lund SJ; Del Rosario PGB; Honda A; Caoili KJ; Hoeksema MA; Nizet V; Patras KA; Prince LS
Immunohorizons; 2024 May; 8(5):384-396. PubMed ID: 38809232
[TBL] [Abstract][Full Text] [Related]
39. The ligand interactions of B cell Siglecs are involved in the prevention of autoimmunity to sialylated self-antigens and in the quality control of signaling-competent B cells.
Tsubata T
Int Immunol; 2023 Oct; 35(10):461-473. PubMed ID: 37504378
[TBL] [Abstract][Full Text] [Related]
40. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion.
Hudak JE; Canham SM; Bertozzi CR
Nat Chem Biol; 2014 Jan; 10(1):69-75. PubMed ID: 24292068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
